Trial Profile
An Open Study of the Safety and Efficacy of Saizen, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2018
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Fetal growth retardation
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 04 May 2014 New trial record